NEWPORT BEACH, Calif., July 22, 2021 (GLOBE NEWSWIRE) — Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2021 financial results and provide a business update on Wednesday, August 4, 2021, after the close of the U.S. financial markets.
Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: +1-949-966-1798
Email: IR@Evolus.com
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Chief Marketing Officer
Tel: +1-949-284-4506
Email: media@evolus.com
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…
RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine…
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity –…
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
